PeptideStack
5.2kquestions
20kanswers
220users

If a retatrutide dose is missed by fourteen days, does the ladder reset?

Asked 13 Jan 2026Modified 4 months agoViewed 11k times
23

Concretely: retatrutide · fourteen days.

This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.

What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.

What does a defensible version of this look like in practice?

missed-dose
missed-dose

What the label instructions for a missed weekly dose are, why they differ between agents, and what the pharmacokinetics say about drift in an…

41 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
shareeditfollowflag
GA
askedgrainne_ahearn50k3813 Jan 2026
Same situation here, so I will follow this one. – Dr_Ingrid_Baumgartner 13 days ago
How long since the last increase? That is the first thing anyone will ask. – Dr_Rosalind_Achebe 9 months ago
add a comment

4 Answers

Sorted by votes
17

14 days past a due dose is 2 half-lives at the seven-day half-life this class runs on, which leaves about 25 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(14÷7) = 0.25. At 25 per cent you have not been off it in any meaningful sense. The interval stretched from 7 days to 21 and the trough went lower than usual; that is the whole of what happened. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.

Never double up to catch up. The exposure spike is real and the tolerability cost is immediate.

Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.

With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.

Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.

Never double up. Peak exposure is what drives the symptoms.

edited 15 Mar 2026 by triple_agonist_q — updated for the 2026 guidance change

shareimprove this answerflag
TQ
answeredtriple_agonist_q57k3819 Feb 2026
Worth flagging that the maximum dose is not the target for most people. – Dr_Aoife_Brennan 6 months ago
Adding that re-titrating after a gap is not optional, as I discovered. – tobias_reint 4 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
11

The underlying point is that changing the regular dosing day is possible and should be done by moving forward, not by squeezing two doses together.

If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.

To change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.

Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.

Nothing here is medical advice, and research-use compounds are not approved for human use.

To move your dosing day, move it later and keep three days between doses.

edited 15 Mar 2026 by ellis_thorne — tightened the wording; no substantive change

shareimprove this answerflag
ET
answeredellis_thorne17k172 Mar 2026
Same experience here, different supplier. – loss_on_drying 8 months ago
add a comment
10

Start with the interval since the missed dose, because that single number determines the answer.

One missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.

For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.

Repeated missed doses are a different problem from an occasional one and should be treated as such.

Set a recurring reminder attached to something you already do weekly.

shareimprove this answerflag
TW
answeredtare_weight60k14813 Mar 2026
6Does the same interval logic apply to the daily agents, or is it shorter? – Dr_Signe_Baldursdottir 6 months ago
5Adding a vote because this deserves more of them. – juan_esquivel 4 months ago
add a comment
7

Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.

The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.

Peak exposure rather than average exposure drives gastrointestinal tolerability, which is the reason doubling up is advised against.

The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.

Within about five days for a weekly agent, take it. Beyond that, skip and resume.

shareimprove this answerflag
KA
answeredkwn_analytical147k35825 Mar 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.